Verily Secures $300 Million Investment To Advance Its Precision Health AI Strategy

Funding round led by Series X Capital, with additional backing from Alphabet, UCHealth, and the University of Colorado Anschutz

DALLAS--(BUSINESS WIRE)--Verily today announced a $300 million investment round led by Series X Capital, with participation from Alphabet, UCHealth, the University of Colorado Anschutz and other investors, to advance the next phase of its precision health AI strategy. With this funding round, Alphabet will be a significant minority investor in Verily, while no longer having a controlling stake.

“Today is an important step in our mission to bring the promise of precision health to everyone,” said Stephen Gillett, Chairman and CEO of Verily. “From research to care, our customers need solutions that bring the best of clinical and scientific rigor together with AI to deliver the next generation of healthcare - one that is as precise as it is personal. Series X Capital, Alphabet, UCHealth, the University of Colorado Anschutz and our many investors will be fantastic partners in this transformation of healthcare.”

With this investment, Verily has transitioned its legal structure from an LLC to a corporation, with the official new name of Verily Health Inc, and plans to accelerate its AI-native precision health platform strategy and roadmap to help customers harmonize their healthcare data, model and deploy actionable intelligence into research and care workflows.

Verily has recently announced a number of commercial partnerships, including a new collaboration with Samsung’s Galaxy Watch to help life sciences customers accelerate clinical research through biomarker development on the Pre platform, and a strategic partnership with Salesforce, announcing integration of the Verily Pre Platform with Agentforce Health to power enterprise precision health solutions. These announcements build on Verily’s recent strategic collaboration with UCHealth, the University of Colorado Anschutz, and RefinedScience who are using the Verily Pre platform for AI-powered research and care transformation.

“Series X Capital was established in collaboration with Google’s X, The Moonshot Factory to scale moonshot technologies into consequential, world-changing companies. We are extremely excited to lead this milestone round for Verily, as they drive commercial momentum as a leader in precision health,” said Gideon Yu, Founder and Managing Partner of Series X Capital.

Verily initially graduated from Google X ten years ago, as one of Alphabet’s earliest “Other Bets”, with a focus on breakthrough science and health tech innovation.

“At Alphabet, we applaud Verily’s tenacity in using technology to address longstanding challenges in the healthcare industry,” said Ruth Porat, President & Chief Investment Officer, Alphabet and Google. “Bringing in new investors, alongside Alphabet’s ongoing involvement, enables Verily to further scale the business to help improve patient outcomes and lower the cost of healthcare delivery through their AI health platform.”

“Partnering with Verily to bring a shared data framework to healthcare data, making it AI‑ready, creates a generational opportunity for UCHealth and for medicine,” said Richard Zane, MD, UCHealth Chief Medical and Innovation Officer. “This collaboration helps unlock the long‑promised potential of personalized care, benefiting our patients and, ultimately, all patients. It will save lives, and we’re eager to get started.”

About Verily Health Inc.
Verily is a data platform and technology company purpose-built to power AI-enabled precision health solutions that accelerate research and improve care for individuals and communities. Uniquely positioned at the intersection of technology, data science, and healthcare, Verily transforms multimodal health data into insights, models, and actions that make healthcare more personalized, predictive, and precise. For more information about Verily please visit: verily.com.

Contacts

Media:
Steven Cooper
Head of Media Relations
sjcoop@verily.com